Manuel Astruc
Psychiatry · Saratoga Springs, NYNPI 1700863255
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,377 of the $19,906 with a category attached, or 67.2%. 26 manufacturers reported payments, led by Brainsway USA Inc at 30.3% of the total. Reporting peaked in 2023 at $9,341 and has fallen 66.3% since, to $3,148 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 820 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Brainsway USA Inc$6K
- AbbVie$4K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$964
- plus $5K from 20 others
What the payments were for
- Consulting fees$3,00015%
- Speaking & faculty fees$3,00015%
- Food & beverage$13,37767%
- Education$5293%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Brainsway USA Inc | 3 | $6,038 |
| AbbVie(2 entities) | 199 | $3,643 |
| Johnson & Johnson | 88 | $1,620 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 77 | $1,244 |
| Teva Pharmaceuticals USA, Inc. | 56 | $1,192 |
| Lundbeck LLC | 61 | $964 |
| Neurocrine Biosciences, Inc. | 56 | $770 |
| Vanda Pharmaceuticals Inc. | 46 | $736 |
| Axsome Therapeutics, Inc. | 46 | $657 |
| Alkermes, Inc. | 32 | $630 |
| Corium, LLC | 34 | $497 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $442 |
| Sunovion Pharmaceuticals Inc. | 33 | $399 |
| Supernus Pharmaceuticals, Inc. | 14 | $242 |
| Otsuka America Pharmaceutical, Inc. | 11 | $210 |
| Idorsia Pharmaceuticals US Inc | 14 | $208 |
| Shire North American Group Inc | 7 | $100 |
| Novo Nordisk | 5 | $84 |
| Bausch Health US, LLC | 4 | $59 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Avanir Pharmaceuticals, Inc. | 2 | $33 |
| Almatica Pharma LLC | 2 | $31 |
| Biogen | 1 | $23 |
| Indivior Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Brainsway Deep TMS$3,000
How this compares
$19,906 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $101,834 |
| VraylarCariprazine Hcl | 47 | $64,745 |
| RexultiBrexpiprazole | 24 | $33,878 |
| TrintellixVortioxetine Hydrobromide | 30 | $15,759 |
| VyvanseLisdexamfetamine Dimesylate | 29 | $10,889 |
| FetzimaLevomilnacipran Hcl | 17 | $8,337 |
| Lurasidone Hcl | 24 | $7,176 |
| Quetiapine Fumarate | 309 | $6,997 |
| Olanzapine | 148 | $6,066 |
| Duloxetine Hcl | 168 | $5,653 |
| Clozapine | 118 | $4,067 |
| Lamotrigine | 292 | $3,963 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 121 | $3,792 |
| Lisdexamfetamine Dimesylate | 20 | $3,391 |
| Clonazepam | 346 | $3,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $770 | $101,83412 claims |
| AbbVieVraylar, Fetzima | $3,643 | $73,08264 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $210 | $33,87824 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $442 | $26,64859 claims |
| Almatica Pharma LLCSertraline Hcl | $31 | $1,131155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Saratoga Springs
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.